This was also fully demonstrated in a retrospective study of nearly 500 patients with lung adenocarcinoma (76), with a higher frequency of EGFR mutations in the TB group than in the non-TB group (56% vs 34%, p=0.038). Here, EGFR is linked to lung adenocarcinoma.